- Molecular NameProtriptyline
- SynonymProtryptyline
- Weight263.384
- Drugbank_IDDB00344
- ACS_NO438-60-8
- Show 3D model
- LogP (experiment)4.9
- LogP (predicted, AB/LogP v2.0)4.23
- pka8.2
- LogD (pH=7, predicted)3.01
- Solubility (experiment)0.00104 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.95
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.09
- No.of HBond Donors1
- No.of HBond Acceptors1
- No.of Rotatable Bonds4
- TPSA12.03
- StatusFDA approved
- AdministrationN/A
- PharmacologyA tricyclic antidepressant (TCA), specifically a secondary amine, indicated for depression and ADHD. Unique among the TCAs, protriptyline tends to be energizing instead of sedating, and it is sometimes used in narcolepsy to achieve a wakefulness-promoting effect.
- Absorption_value95.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability85.0
- Protein binding92.0
- Volume of distribution (VD)22 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life4 days
- ExcretionRenal, in urine
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects include anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal problems.
- LD50 (rat)N/A
- LD50 (mouse)LD50=100 (ip)